Renaissance Capital logo

Ambit Biosciences Priced, Nasdaq: AMBI.XX

Developing small molecule therapeutics for the treatment of acute myeloid leukemia.

Industry: Health Care

First Day Return: -7.6%

Developing small molecule therapeutics for the treatment of acute myeloid leukemia.
IPO Data
IPO Date 05/15/2013
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $65
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters San Diego, CA, United States
Founded 2000
Employees at IPO 45
Website www.ambitbio.com

Ambit Biosciences (AMBI.XX) Performance

Created with Highcharts 10.3.2Chart context menuAMBI.XX vs. IPO Index (IPOUSA)2014201520162017201820192020202120222023202420250%+ 200%+ 400%-200%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index